MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 мар 2024 22:58:56 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

18 мар 2024 15:04:05 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 мар 2024 15:15:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

05 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

28 фев 2024 06:01:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

28 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

08 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

29 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

04 янв 2024 07:00:01 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 15:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 дек 2023 15:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 ноя 2023 15:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 ноя 2023 15:45:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire